

Research in Your Backyard

Developing Cures, Creating Jobs



**PHARMACEUTICAL
CLINICAL TRIALS IN
MASSACHUSETTS**

Dots show locations of clinical trials in the state.

Executive Summary

Clinical Trials in Massachusetts

- Biopharmaceutical research companies are conducting or have conducted more than 4,700 clinical trials of new medicines in collaboration with the state's university medical schools, clinical research centers and hospitals (1999 to present).
- Of the more than 4,700 clinical trials, 2,483 target the nation's six most debilitating chronic diseases—**asthma, cancer, diabetes, heart disease, mental illnesses and stroke.**

Economic Benefits of Clinical Trials in Massachusetts

- Biopharmaceutical research companies have been a source of jobs, tax revenue and research spending in Massachusetts.
- A study by Battelle Technology Partnership Practice found that in 2011 the industry supported more than 179,000 jobs throughout the state.
- Wages and benefits for employees whose jobs were supported by the biopharmaceutical sector resulted in about \$971 million in federal taxation and \$173 million in state taxes.
- Biopharmaceutical research companies generated \$38 billion in goods and services in the state, including the direct economic output of the sector itself, the output of the sector's vendors and

“Clinical research in central Massachusetts allows our researchers to be involved in the development of important new medicines for patients. Clinical trials of new medications conducted by biopharmaceutical research companies in collaboration with our research institutions have allowed talented clinicians at facilities in the Worcester area to be engaged in cutting-edge biopharmaceutical science. Treatment trials that target cancer, heart disease and stroke are among the trials being conducted in our area and that has benefited such institutions as the University of Massachusetts Medical School, Reliant Medical Group at Worcester Medical Center and Saint Vincent Hospital. In other words, this partnership with innovative biopharmaceutical companies has been beneficial to both patients and the local economy.”

—Tim Murray
President and CEO
Worcester Regional Chamber of Commerce

suppliers and the output generated by the buying power of its workforce.

- Company employees in Massachusetts include life sciences researchers, management executives, office and administrative support workers, production workers, engineers, architects, computer and math

“The thousands of clinical trials of new medicines that biopharmaceutical companies have conducted in our state, including the 504 of potential new chronic disease medicines that are still underway, are a boost to not only patients, but also the Massachusetts economy and scientific progress. They benefit the economy because the companies have wisely tapped the expertise of our research facilities along with the greater need for biomanufacturing in-state to conduct the trials as they contribute to advances in science. Many of the medications clinically tested here have been cutting-edge biotechnology treatments with the potential to be safer and more effective.”

—Kevin O’Sullivan
 President and CEO
 Massachusetts Biomedical Initiatives

experts and sales representatives. Biopharmaceutical companies also supported the jobs of their vendors and suppliers, including construction and IT firms. And the employees of biopharmaceutical companies help to support local restaurants, day care centers and other community businesses.

About Clinical Trials

- In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration (FDA) to approve treatments.
- Clinical tests of new drugs are conducted in three phases and account for an average of seven of the 10 to 15 years it takes to bring a new drug from development to patients.
- Clinical trials for a given drug or treatment involve thousands of volunteer patient participants, and the

generation of tens of thousands of pages of technical and scientific data.

- Clinical trials are responsible for 45 to 75 percent of the \$1.2 billion average cost of developing one new cutting-edge biotechnology medicine.
- For patients, the trials offer another potential therapeutic option. Clinical tests may provide a new avenue of care for some chronic disease sufferers who are still searching for the medicines that are best for them.
- Some trials are also conducted to compare existing treatments while others are done to learn if a drug is appropriate for a particular patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.
- All clinical trials must be reviewed and approved by an Institutional Review Board (IRB), an independent committee of physicians, statisticians, local community advocates and others to ensure a trial is ethically conducted and patient rights are protected.
- Clinical trial progress reports must be submitted at least annually to the FDA and IRB.
- All facilities that conduct or support biomedical research involving patients must comply with federal regulations and have an IRB.

Clinical Trials in Massachusetts since 1999—Completed and Active

All Clinical Trials	Six Major Chronic Diseases
4,710	2,483

Source: www.clinicaltrials.gov
 Note: Search criteria = Massachusetts, United States; Phase 0, 1, 2, 3; industry only. Search performed 10/18/2013.

Clinical Trials and Chronic Diseases

- Chronic diseases pose the greatest threats to our nation’s health and our ability to treat and prevent medical conditions.
- According to the U.S. Centers for Disease Control and Prevention (CDC), today, in the United States:
 - > Patients with chronic diseases **account for 75 cents of every dollar** spent on health care.

- > Chronic diseases are the **leading cause of death and disability.**
- > Chronic diseases are a **leading driver of rising health care costs** with expenses totaling billions of dollars every year.

Clinical Trials in Massachusetts Communities						
Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Belmont	—	—	—	—	4	—
Boston	2	359	10	32	24	9
Brockton	1	—	4	—	2	—
Burlington	—	13	—	1	1	1
Fall River	—	—	5	4	2	4
Haverhill	—	1	—	3	2	4
Hyannis	—	2	1	2	—	1
North Dartmouth	8	—	—	—	—	—
Springfield	1	3	2	1	1	1
Watertown	1	—	2	1	4	1
Worcester	—	29	2	4	—	3

Source: www.clinicaltrials.gov

Note: Search criteria = Massachusetts, United States; Phase 0, 1, 2, 3; industry only. Search performed 10/18/2013. See Appendix for detailed information about these clinical trials. **Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city. This list of cities and towns is representative and not a complete list of where clinical trials are taking place in Massachusetts.**

- Biopharmaceutical research companies are developing new medicines to help treat those conditions that are taking an unprecedented toll on American lives, and many of these medicines are being tested today in clinical trials throughout Massachusetts.
- Since 1999, biopharmaceutical research companies are sponsoring or have sponsored 2,483 clinical trials of potential new medicines in Massachusetts alone for **asthma, cancer, heart disease, stroke, diabetes and mental illnesses**. Of these trials, 504 are either not yet recruiting or are just now seeking Massachusetts

patients. The 504 trials are being conducted at nearly 800 sites in Massachusetts.

- Biopharmaceutical companies are collaborating on the tests with such prominent institutions as the **University of Massachusetts Medical School, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital and Boston University**.
- Some of the medicines being clinically tested in Massachusetts are new-generation biotechnology treatments.

“The Leukemia & Lymphoma Society exists to find cures and ensure access to treatments for all blood cancer patients. Clinical trials are a critical step in the process of advancing new potentially life-saving or life-extending therapies for patients with blood cancers and other serious diseases, and taking part in a clinical trial may be the best treatment choice for some patients. LLS supports important research at many renowned academic institutions and biotechnology companies in Massachusetts, across the spectrum from bench to bedside research.”

—Maida Milone
Senior Region Mission Director – Northeast
The Leukemia & Lymphoma Society

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	107	12
Cancer	1,487	382
Diabetes	245	23
Heart Disease	222	36
Mental Illness	376	39
Stroke	46	12
Total	2,483	504

Source: www.clinicaltrials.gov

Note: Search criteria = Massachusetts, United States; Phase 0, 1, 2, 3; industry only. Search performed 10/18/2013. **Some clinical trials appear in more than one disease category.**

Clinical Trials in Massachusetts

Clinical tests of new medicines are a vitally important part of the drug development and approval process—they account for 45 to 75 percent of the \$1.2 billion average cost of developing a new drug and are conducted to determine the safety and effectiveness of that treatment in patients.

Some trials are also conducted to compare existing treatments and some are done to explore whether a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.

It's essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines when used by patients. The FDA is a vigilant regulatory agency and its pharmaceutical review officers are effective in detecting flawed information.

Questionable or confusing data can lead to lengthy delays in product approval or outright FDA rejection of a new drug.

Biopharmaceutical research companies are looking for the best physicians and research institutions to meticulously help design and conduct their clinical trials to determine whether a medicine is safe and effective. Side effects must be painstakingly documented and a determination made as to whether they occur too often and are dangerous.

Clinical tests involve three phases, thousands of volunteer patients, and are often conducted at multiple sites around the country.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	107	12
Cancer	1,487	382
Diabetes	245	23
Heart Disease	222	36
Mental Illness	376	39
Stroke	46	12
Total	2,483	504

Source: www.clinicaltrials.gov

Note: Search criteria = Massachusetts, United States; Phase 0, 1, 2, 3; industry only. Search performed 10/18/2013. **Some clinical trials appear in more than one disease category.**

In Massachusetts, biopharmaceutical companies are providing funds to have trials conducted at the states' well-respected medical schools, hospitals and clinical research organizations. According to *U.S. News and World Report*, **Harvard University** ranked 1st, **Boston University** ranked 30th, the **University of Massachusetts-Worcester** ranked 46th and **Tufts University** ranked 51st among this year's top 100 research-oriented medical schools in the United States.

Asthma is a debilitating condition for more than 25 million Americans, including 7.1 million children under the age of 18. The toll is also severe in Massachusetts, where more than 600,000 residents suffer from asthma, according to the U.S. Centers for Disease Control and Prevention.

Currently, 12 clinical trials of new asthma medicines are recruiting patients in Massachusetts. The majority of the trials are being conducted in **Boston** and **North Dartmouth**.

Cancer, the second leading cause of death in the United States, now afflicts nearly 14 million Americans, according to the National Cancer Institute. In Massachusetts, more than 38,000 new cancer cases will be diagnosed this year and 12,840 victims in the state will die, according to the American Cancer Society.

Currently, 382 clinical trials of new cancer medicines are recruiting patients in Massachusetts. In Boston, biopharmaceutical companies are collaborating on the tests with such prominent institutions as the **Dana Farber Cancer Institute**, **Brigham and Women's Hospital**, **Beth Israel Deaconess Medical Center** and **Massachusetts General Hospital**. Other trials are being conducted at the **University of Massachusetts Medical School** in Worcester and **Lahey Hospital and Medical Center** in Burlington.

Diabetes affects more than 25 million Americans—more than 8 percent of the U.S. population—including 7 million people who are unaware they have the disease. In Massachusetts, about 7 percent of adults have been diagnosed with diabetes and another 4.1 percent have pre-diabetes, according to the Massachusetts Department of Public Health.

Currently, 23 diabetes clinical tests are seeking patients in Massachusetts. The trials are being conducted at the **Joslin Diabetes Center** and **Massachusetts General Hospital** in Boston, the **University of Massachusetts Medical School** in Worcester and **Beacon Clinical Research** in Brockton.

Heart disease and stroke are the first and fourth leading disease causes of death in the United States and the second and third in Massachusetts. According to the American Heart Association, more than 82 million Americans are affected by these diseases. In Massachusetts, in 2009, more than 12,000 residents died from some form of heart disease and 2,552 died from a stroke, according to the Massachusetts Department of Public Health.

Currently, 36 heart disease and 12 stroke clinical tests are seeking patients in Massachusetts. The trials are being conducted at the **Caritas St. Elizabeth's Medical Center**, **Tufts Medical Center** and **Massachusetts General Hospital Heart Center** in Boston, the **University of Massachusetts Medical School** in Worcester, **Berkshire Medical Center** in Pittsfield and **Metrowest Medical Center** in Framingham.

Mental illness affects nearly 60 million Americans who suffer from some form of the disease—from anxiety to depression to schizophrenia to eating disorders. In Massachusetts, about 211,000 adults live with serious mental illness and about 67,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness.

Currently, 39 clinical trials for mental illness are recruiting patients in Massachusetts. The trials are taking place at the **Boston University Alzheimer's Disease Center** and **Massachusetts General Hospital** in Boston, the **Quincy Medical Center Alzheimer's Disease Center** in Quincy, **McLean Hospital** in Belmont and the **Lahey Clinic** in Burlington.

Physicians and patients can find out about clinical trials being conducted all over the state in collaboration with local institutions by accessing www.clinicaltrials.gov, a database sponsored by the National Institutes of Health. Information on clinical trials and medicines in development is also available on www.phrma.org, the website of the Pharmaceutical Research and Manufacturers of America (PhRMA). Click on Innovation, Clinical Trials and then Research in Your Backyard.

What is the Clinical Trial Experience?

Clinical trials are research studies that grant participants early access to new medicines, which are being developed to help combat chronic and serious diseases. By volunteering for a clinical trial, patients take an active role in their healthcare by helping researchers test new treatments. In Massachusetts alone, thousands of clinical trials have been conducted to target chronic conditions like asthma, cancer, diabetes, heart disease, mental illness and stroke.

Phases of Clinical Trials

There are three phases of testing used to evaluate potential new medicines:

Phase I—This phase is designed to test the safety of a new medicine. Researchers test the drug on a small group of people (20-80) and evaluate safety aspects of the drug, such as safe dosage range, the best way of administering the treatment (pill form vs. a shot, for example) and identifying what, if any, side effects there may be.

Phase II—This phase is designed to test effectiveness and safety. The treatment is given to 100 to 300 people to assess efficacy and try to identify less common side effects, which may appear when more people are tested. This phase is usually placebo-controlled and double-blinded—neither patients nor doctors know if the patient is getting placebo or the medicine.

Phase III—This phase is designed to confirm effectiveness and safety, monitor side effects and compare the unapproved drug being tested to commonly used medications from the market to determine which is more effective. A large group (1,000-3,000) receives this treatment, and like Phase II, it is usually placebo-controlled and double-blinded.

Learning About and Accessing Clinical Trials

Patients can learn about clinical trials several ways. Healthcare providers are aware of clinical trials being conducted at hospitals, universities and other leading healthcare facilities, and these institutions can be valuable sources of information for patients looking to participate. Patients can also use hospital and university websites to find the trials being conducted in their area. More information about clinical trials and how to volunteer for one can be found at <http://centerwatch.com>, a PhRMA-recommended website.

What to Expect

Since clinical trials are often conducted in a doctor's office, patients may need to devote more time to physician visits and physical examinations. They may also have additional responsibilities, like keeping a daily log

of their health. All prospective participants must sign an informed consent document saying they understand that the clinical trial is research, and that they can leave the trial at any time. After consulting with their healthcare providers, patients can volunteer to participate, leading to a pre-screening interview. If they fit the criteria and requirements of the test, they can be enrolled.

Patient Expenses

Patients should ask during pre-screening interviews what it will cost them to participate in a clinical trial. Clinical trial sponsors usually pay for all research-related expenses and additional testing or physician visits required by the trial. Patients or their insurance companies may be asked to pay for any routine treatments of their disease. And it's important to know some health plans do not pay for clinical trials. Patients should make it a point to learn if they or their insurance company will be assessed any fees and should determine if their insurance company will cover the expense of routine examinations. Patients who live a distance from the trial site should learn the clinic's policy for covering travel costs and living expenses.

The National Cancer Institute, for example, makes patients responsible for their own travel costs for the initial screening visits. Once a patient is enrolled, the Institute will pay for transportation costs for all subsequent trial-related visits. These patients will receive a small per diem for food and lodging.

New Generation Medicines in Development

Some of the medicines that have been tested in Massachusetts are cutting-edge biotechnology drugs.

America's biopharmaceutical research companies are using biotechnology to develop hundreds of new medicines and vaccines today. And Massachusetts is one of the states where this research and development work is being done.

Through biotechnology, new ways are being developed to not only more effectively treat disease, but also to predict and even prevent it.

Biotechnology medicines are developed through biological processes using living cells or organisms, rather than traditional chemical synthesis, the mainstay of pharmaceutical development for decades.

Such novel treatments use a variety of new approaches to treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology is being used in biotechnology research to provide drug-delivery systems, new treatments and diagnostics.

Some of the medicines in clinical testing, and those that have already been tested at Massachusetts hospitals

and research centers feature these technologies. For example:

- A genetically-modified virus-based vaccine to treat melanoma is being studied at **Massachusetts General Hospital Cancer Center** in Boston.
- A monoclonal antibody for the treatment of idiopathic pulmonary fibrosis is in clinical trials at **Steward St. Elizabeth Medical Center** in Boston.
- A recombinant fusion protein to treat diabetic macular edema is being studied in clinical trials at **Joslin Diabetes Center** and **Ophthalmic Consultants of Boston** in Boston and **Vitreo-Retinal Associates** in Worcester.
- A therapeutic vaccine, designed to jump-start the immune system to fight disease, is in development for lung cancer and melanoma in **Boston** and **Worcester**.
- An engineered human antibody to reduce inflammation in psoriasis is in clinical trials in **Andover, Boston, Methuen** and **Worcester**.

The biotechnology medicines and vaccines that are being developed today are helping to expand the frontiers of science and that could lead to more and better treatments for patients. In Massachusetts, as in other states, this innovation is the result of a successful collaboration of biopharmaceutical companies and local research institutions.

Conclusion

Biopharmaceutical research companies' close collaboration with clinicians and research institutions in Massachusetts benefits patients, the state's economy and the advancement of science and patient care. Clinical trials provide stimulating biopharmaceutical research work and a reliable source of revenue for the states' medical schools, hospitals and local contract research organizations, and the medicines being tested are sometimes cutting-edge

cell and protein treatments with the potential to be safer and more effective than older chemical compound drugs.

What's more, Bay Staters considering participation in clinical trials have a wide range of choices, including 504 tests of new medicines for the six most debilitating chronic diseases.

The Drug Discovery, Development and Approval Process

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Clinical Trials						
	Discovery/ Preclinical Testing	Phase I	Phase II	Phase III	FDA	Phase IV
Years	6.5	1.5	2	3.5	1.5	
Test Population	Laboratory and animal studies	20 to 80 healthy volunteers	100 to 300 patient volunteers	1,000 to 3,000 patient volunteers	Review process/ approval	Additional post-marketing testing required by FDA
Purpose	Assess safety, biological activity and formulations	Determine safety and dosage	Evaluate effectiveness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use		
Success Rate	5,000 compounds evaluated	5 enter trials			1 approved	

The Drug Development and Approval Process

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company \$1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are usually developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test

the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I—Researchers test the drug in a small group of people, usually between 20 and 80 healthy adult volunteers, to evaluate its initial safety and tolerability profile, determine a safe dosage range, and identify potential side effects.

Clinical Trials, Phase II—The drug is given to volunteer patients, usually between 100 and 300, to see if it is effective, identify an optimal dose, and further evaluate its short-term safety.

Clinical Trials, Phase III—The drug is given to a larger, more diverse patient population, often involving between 1,000 and 3,000 patients (but sometime many more thousands),

to generate statistically significant evidence to confirm its safety and effectiveness. They are the longest studies, and usually take place in multiple sites around the world.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated \$48.5 billion in research and development in 2012.

The Good News – Many Clinical Trials are Still Recruiting

There are 504 clinical trials of new chronic disease drugs recruiting patients in Massachusetts. These trials target the most debilitating chronic conditions—cancer, heart disease, stroke, asthma, diabetes and mental illness.

Clinical Trials in Massachusetts Communities						
Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Belmont	—	—	—	—	4	—
Boston	2	359	10	32	24	9
Brockton	1	—	4	—	2	—
Burlington	—	13	—	1	1	1
Fall River	—	—	5	4	2	4
Haverhill	—	1	—	3	2	4
Hyannis	—	2	1	2	—	1
North Dartmouth	8	—	—	—	—	—
Springfield	1	3	2	1	1	1
Watertown	1	—	2	1	4	1
Worcester	—	29	2	4	—	3

Source: www.clinicaltrials.gov

Note: Search criteria = Massachusetts, United States; Phase 0, 1, 2, 3; industry only. Search performed 10/18/2013. See Appendix for detailed information about these clinical trials. **Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city. This list of cities and towns is representative and not a complete list of where clinical trials are taking place in Massachusetts.**

The Good News—Many Clinical Trials are Still Recruiting

(continued)

Cancer—Leading Institutions Conducting Clinical Trials

Baystate Medical Center, Springfield
Beth Israel Deaconess Medical Center, Boston
Boston Children’s Hospital, Boston
Boston University Medical Center, Boston
Brigham and Women’s Cancer Center, Boston
Cape Cod Hospital, Hyannis
Commonwealth Hematology-Oncology, Lawrence
Dana-Farber Cancer Institute, Boston
Fallon Clinic at Worcester Medical Center, Worcester
Faulkner Hospital, Boston
Lahey Hospital & Medical Center, Burlington
Massachusetts Eye & Ear Infirmary, Boston
Massachusetts General Hospital, Boston
Milford Hospital, Milford
Newton Wellesley Hospital, Newton
Reliant Medical Group, Worcester
South Shore Hospital, Weymouth
Tufts Cancer Center, Boston
University of Massachusetts Medical School, Worcester
VA Boston Healthcare System, Jamaica Plain

Diabetes—Leading Institutions Conducting Clinical Trials

Beacon Clinical Research, Brockton
Beth Israel Deaconess Medical Center, Boston
Boston University Medical Center, Boston

Genesis Clinical Research, Fall River
Infosphere Clinical Research, Newton
Joslin Diabetes Center, Boston

Heart Disease—Leading Institutions Conducting Clinical Trials

Berkshire Medical Center, Pittsfield
Beth Israel Deaconess Medical Center, Boston
Boston Children’s Hospital, Boston
Boston University, Boston
Brigham and Women’s Hospital, Boston
Caritas St. Elizabeth’s Medical Center, Boston
Massachusetts General Hospital, Boston
Metrowest Medical Center, Framingham
Tufts Medical Center, Boston
University of Massachusetts Medical School, Worcester

Mental Illness—Leading Institutions Conducting Clinical Trials

Activmed Practices & Research, Haverhill
Adams Clinical Trials, Watertown
Beacon Clinical Research, Brockton
Beth Israel Deaconess Medical Center, Boston
Boston Clinical Trials, Boston
Boston University Alzheimer’s Disease Center, Boston
Brigham and Women’s Hospital, Boston
Lahey Clinic, Burlington
Massachusetts General Hospital, Boston

McLean Hospital, Belmont
Mood and Anxiety Disorders Research Program,
Cambridge
Neurocare, Newton
New England Center for Clinical Research, Fall River
Quincy Medical Center Alzheimer's Disease Center,
Quincy
Sleep Health Centers, Brighton
Springfield Neurology Associates, Springfield

Stroke—Leading Institutions Conducting Clinical Trials

Beth Israel Deaconess Medical Center, Boston
Boston University, Boston
Massachusetts General Hospital, Boston
Tufts Medical Center, Boston
University of Massachusetts Medical School,
Worcester

Appendix

The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto *www.clinicaltrials.gov*, the clinical tests database of the National Institutes of Health.

Asthma

(12 clinical trials recruiting)

Study 1:

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

<http://ClinicalTrials.gov/show/NCT01634152>

Study 2:

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

<http://ClinicalTrials.gov/show/NCT01479595>

Study 3:

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

<http://ClinicalTrials.gov/show/NCT01478360>

Study 4:

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Inadequately Controlled Asthma Subjects With High Bronchodilator Reversibility

<http://ClinicalTrials.gov/show/NCT01902290>

Study 5:

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (Mcg), FF/VI 100/25 Mcg, and FF 100 Mcg in Adults and Adolescents With Persistent Asthma

<http://ClinicalTrials.gov/show/NCT01686633>

Study 6:

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

<http://ClinicalTrials.gov/show/NCT01959412>

Study 7:

A Study of Lebrikizumab in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication

<http://ClinicalTrials.gov/show/NCT01868061>

Study 8:

Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011 AM2)

<http://ClinicalTrials.gov/show/NCT01624974>

Study 9:

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

<http://ClinicalTrials.gov/show/NCT01673672>

Study 10:

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

<http://ClinicalTrials.gov/show/NCT01836471>

Study 11:

Evaluate Safety of T/I on Diabetic Subjects With Mild Obstructive Pulmonary Disease

<http://ClinicalTrials.gov/show/NCT00642616>

Study 12:

Long-Term Efficacy and Safety Study of SCH 900237/ MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

<http://ClinicalTrials.gov/show/NCT01700192>

Cancer

(382 clinical trials recruiting)

Study 1:

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01421472>

Study 2:

A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01237678>

Study 3:

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

<http://ClinicalTrials.gov/show/NCT01891344>

Study 4:

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

<http://ClinicalTrials.gov/show/NCT01666444>

Study 5:

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

<http://ClinicalTrials.gov/show/NCT00858364>

Study 6:

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01493505>

Study 7:

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

<http://ClinicalTrials.gov/show/NCT01379534>

Study 8:

Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01335958>

Study 9:

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01345019>

Study 10:

A Study of Onartuzumab (MetMAB) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

<http://ClinicalTrials.gov/show/NCT01456325>

Study 11:

A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01588028>

Study 12:

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01248949>

Study 13:

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

<http://ClinicalTrials.gov/show/NCT01482715>

Study 14:

A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

<http://ClinicalTrials.gov/show/NCT01106352>

Study 15:

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01322490>

Study 16:

Safety, PK of AKT and MEK Combination

<http://ClinicalTrials.gov/show/NCT01138085>

Study 17:

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

<http://ClinicalTrials.gov/show/NCT01451632>

Study 18:

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01309126>

Study 19:

Safety Study of MGA271 in Refractory Cancer

<http://ClinicalTrials.gov/show/NCT01391143>

Study 20:

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

<http://ClinicalTrials.gov/show/NCT01170650>

Study 21:

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

<http://ClinicalTrials.gov/show/NCT01390818>

Study 22:

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

<http://ClinicalTrials.gov/show/NCT01874353>

Study 23:

Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy

<http://ClinicalTrials.gov/show/NCT01844986>

Study 24:

Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01375842>

Study 25:

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

<http://ClinicalTrials.gov/show/NCT01607957>

Study 26:

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01427946>

Study 27:

Neratinib With and Without Temezirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01827267>

Study 28:

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

<http://ClinicalTrials.gov/show/NCT01783444>

Study 29:

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

<http://ClinicalTrials.gov/show/NCT01479244>

Study 30:

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

<http://ClinicalTrials.gov/show/NCT01420081>

Study 31:

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01839487>

Study 32:

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01296555>

Study 33:

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

<http://ClinicalTrials.gov/show/NCT01396148>

Study 34:

A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01652482>

Study 35:

Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01493843>

Study 36:

Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Patients

<http://ClinicalTrials.gov/show/NCT01611558>

Study 37:

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

<http://ClinicalTrials.gov/show/NCT01641939>

Study 38:

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01297491>

Study 39:

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01395758>

Study 40:

A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01871805>

Study 41:

Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01642004>

Study 42:

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01616758>

Study 43:

A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01862081>

Study 44:

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

<http://ClinicalTrials.gov/show/NCT01437566>

Study 45:

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

<http://ClinicalTrials.gov/show/NCT01598077>

Study 46:

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

<http://ClinicalTrials.gov/show/NCT01708161>

Study 47:

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01576666>

Study 48:

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01940172>

Study 49:

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01338831>

Study 50:

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

<http://ClinicalTrials.gov/show/NCT01209195>

Study 51:

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

<http://ClinicalTrials.gov/show/NCT01578239>

Study 52:

SGI-110 in Combination With Carboplatin in Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01696032>

Study 53:

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

<http://ClinicalTrials.gov/show/NCT01602406>

Study 54:

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

<http://ClinicalTrials.gov/show/NCT01613950>

Study 55:

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01578655>

Study 56:

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01719380>

Study 57:

Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01936363>

Study 58:

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01677455>

Study 59:

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

<http://ClinicalTrials.gov/show/NCT01911325>

Study 60:

Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01820325>

Study 61:

Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01745367>

Study 62:

Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT01857193>

Study 63:

Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) Non-Small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01526928>

Study 64:

A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT00585195>

Study 65:

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01692262>

Study 66:

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

<http://ClinicalTrials.gov/show/NCT01219699>

Study 67:

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

<http://ClinicalTrials.gov/show/NCT01712217>

Study 68:

Study of a Drug [DCVax[®]-L] to Treat Newly Diagnosed GBM Brain Cancer

<http://ClinicalTrials.gov/show/NCT00045968>

Study 69:

A Study of AMG 337 in Subjects With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01253707>

Study 70:

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

<http://ClinicalTrials.gov/show/NCT00680992>

Study 71:

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, in Patients With Locally Recurrent Or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT00960960>

Study 72:

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01621243>

Study 73:

A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

<http://ClinicalTrials.gov/show/NCT01711970>

Study 74:

Video Impact on Neulasta Education

<http://ClinicalTrials.gov/show/NCT01752907>

Study 75:

A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113

<http://ClinicalTrials.gov/show/NCT01449461>

Study 76:

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

<http://ClinicalTrials.gov/show/NCT01872260>

Study 77:

Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

<http://ClinicalTrials.gov/show/NCT01751308>

Study 78:

A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

<http://ClinicalTrials.gov/show/NCT01896531>

Study 79:

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

<http://ClinicalTrials.gov/show/NCT01409135>

Study 80:

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

<http://ClinicalTrials.gov/show/NCT01517802>

Study 81:

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01436968>

Study 82:

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01772797>

Study 83:

A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

<http://ClinicalTrials.gov/show/NCT01336634>

Study 84:

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01709734>

Study 85:

L-BLP25 (Stimuvax) in Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01496131>

Study 86:

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer

<http://ClinicalTrials.gov/show/NCT01617668>

Study 87:

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01847274>

Study 88:

Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

<http://ClinicalTrials.gov/show/NCT01843062>

Study 89:

The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01506609>

Study 90:

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01220128>

Study 91:

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01685138>

Study 92:

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

<http://ClinicalTrials.gov/show/NCT01609556>

Study 93:

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

<http://ClinicalTrials.gov/show/NCT01792687>

Study 94:

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT01698918>

Study 95:

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01525589>

Study 96:

Study of ARN-810 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01823835>

Study 97:

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT01304797>

Study 98:

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer

<http://ClinicalTrials.gov/show/NCT01602380>

Study 99:

Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

<http://ClinicalTrials.gov/show/NCT01337089>

Study 100:

A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

<http://ClinicalTrials.gov/show/NCT01524978>

Study 101:

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

<http://ClinicalTrials.gov/show/NCT01610284>

Study 102:

Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC

<http://ClinicalTrials.gov/show/NCT01673867>

Study 103:

AZD9291 First Time In Patients Ascending Dose Study

<http://ClinicalTrials.gov/show/NCT01802632>

Study 104:

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT01828021>

Study 105:

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

<http://ClinicalTrials.gov/show/NCT01471210>

Study 106:

STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01765582>

Study 107:

Study of MK-3475 in Participants With Advanced Solid Tumors (MK-3475-012)

<http://ClinicalTrials.gov/show/NCT01848834>

Study 108:

A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

<http://ClinicalTrials.gov/show/NCT01351415>

Study 109:

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01740336>

Study 110:

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

<http://ClinicalTrials.gov/show/NCT01395914>

Study 111:

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

<http://ClinicalTrials.gov/show/NCT01387269>

Study 112:

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001)

<http://ClinicalTrials.gov/show/NCT01295827>

Study 113:

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01663727>

Study 114:

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

<http://ClinicalTrials.gov/show/NCT01363232>

Study 115:

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

<http://ClinicalTrials.gov/show/NCT01345669>

Study 116:

Continuation Study of the Oral AKT Inhibitor GSK2110183

<http://ClinicalTrials.gov/show/NCT01531894>

Study 117:

A Study Of PF-06263507 In Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01891669>

Study 118:

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01479465>

Study 119:

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

<http://ClinicalTrials.gov/show/NCT00559117>

Study 120:

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

<http://ClinicalTrials.gov/show/NCT01487785>

Study 121:

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

<http://ClinicalTrials.gov/show/NCT01628913>

Study 122:

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

<http://ClinicalTrials.gov/show/NCT01685060>

Study 123:

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

<http://ClinicalTrials.gov/show/NCT01828112>

Study 124:

Everolimus Plus Best Supportive Care vs. Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

<http://ClinicalTrials.gov/show/NCT01524783>

Study 125:

BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy

<http://ClinicalTrials.gov/show/NCT01658436>

Study 126:

A Study of LY2875358 in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01287546>

Study 127:

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01394016>

Study 128:

A Study of MPDL3280A in Combination With Avastin (Bevacizumab) or With Avastin Plus FOLFOX in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01633970>

Study 129:

E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

<http://ClinicalTrials.gov/show/NCT01433991>

Study 130:

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

<http://ClinicalTrials.gov/show/NCT00953576>

Study 131:

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00994123>

Study 132:

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

<http://ClinicalTrials.gov/show/NCT01364415>

Study 133:

Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer

<http://ClinicalTrials.gov/show/NCT01921335>

Study 134:

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

<http://ClinicalTrials.gov/show/NCT01461538>

Study 135:

Trastuzumab and Vinorelbine in Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT01185509>

Study 136:

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

<http://ClinicalTrials.gov/show/NCT01747876>

Study 137:

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

<http://ClinicalTrials.gov/show/NCT01191697>

Study 138:

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

<http://ClinicalTrials.gov/show/NCT00813293>

Study 139:

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01673737>

Study 140:

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01912963>

Study 141:

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

<http://ClinicalTrials.gov/show/NCT01594723>

Study 142:

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma

<http://ClinicalTrials.gov/show/NCT01237236>

Study 143:

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

<http://ClinicalTrials.gov/show/NCT01207492>

Study 144:

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

<http://ClinicalTrials.gov/show/NCT01345682>

Study 145:

A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01629615>

Study 146:

GSK1120212+GSK2141795 for Cervical Cancer

<http://ClinicalTrials.gov/show/NCT01958112>

Study 147:

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

<http://ClinicalTrials.gov/show/NCT00936858>

Study 148:

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

<http://ClinicalTrials.gov/show/NCT00854152>

Study 149:

Patient Controlled Tissue Expansion for Breast Reconstruction

<http://ClinicalTrials.gov/show/NCT01425268>

Study 150:

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

<http://ClinicalTrials.gov/show/NCT01750580>

Study 151:

A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01714739>

Study 152:

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT00470704>

Study 153:

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01449058>

Study 154:

Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling

<http://ClinicalTrials.gov/show/NCT01942837>

Study 155:

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

<http://ClinicalTrials.gov/show/NCT00932451>

Study 156:

Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit

<http://ClinicalTrials.gov/show/NCT01087697>

Study 157:

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

<http://ClinicalTrials.gov/show/NCT00697632>

Study 158:

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

<http://ClinicalTrials.gov/show/NCT00611858>

Study 159:

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01705483>

Study 160:

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01543698>

Study 161:

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

<http://ClinicalTrials.gov/show/NCT01922752>

Study 162:

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01441947>

Study 163:

A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01288989>

Study 164:

A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01240655>

Study 165:

A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01664000>

Study 166:

A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

<http://ClinicalTrials.gov/show/NCT01874665>

Study 167:

MSB0010718C in Solid Tumors

<http://ClinicalTrials.gov/show/NCT01772004>

Study 168:

Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies

<http://ClinicalTrials.gov/show/NCT01058707>

Study 169:

The Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Pediatric Subjects

<http://ClinicalTrials.gov/show/NCT01677741>

Study 170:

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

<http://ClinicalTrials.gov/show/NCT01433263>

Study 171:

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

<http://ClinicalTrials.gov/show/NCT01624285>

Study 172:

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

<http://ClinicalTrials.gov/show/NCT01681433>

Study 173:

A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01760525>

Study 174:

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421 (SAR153192) in Patients With Advanced Solid Malignancies

<http://ClinicalTrials.gov/show/NCT00871559>

Study 175:

REDECT 2: RENal Masses: Pivotal Trial to DEtect Clear Cell Renal Cell Carcinoma With PET/CT

<http://ClinicalTrials.gov/show/NCT01762592>

Study 176:

Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01449370>

Study 177:

A Study of MEHD7945A in Combination With Cisplatin and 5-FU or Paclitaxel and Carboplatin on Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

<http://ClinicalTrials.gov/show/NCT01911598>

Study 178:

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

<http://ClinicalTrials.gov/show/NCT01436656>

Study 179:

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

<http://ClinicalTrials.gov/show/NCT00968968>

Study 180:

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

<http://ClinicalTrials.gov/show/NCT01647711>

Study 181:

Everolimus Versus Placebo in Head and Neck Cancer

<http://ClinicalTrials.gov/show/NCT01111058>

Study 182:

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

<http://ClinicalTrials.gov/show/NCT01301716>

Study 183:

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

<http://ClinicalTrials.gov/show/NCT00116142>

Study 184:

A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer

<http://ClinicalTrials.gov/show/NCT01270321>

Study 185:

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors

<http://ClinicalTrials.gov/show/NCT01562275>

Study 186:

A Study of LY2940680 in Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01722292>

Study 187:

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT00999401>

Study 188:

A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy

<http://ClinicalTrials.gov/show/NCT01954745>

Study 189:

Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy

<http://ClinicalTrials.gov/show/NCT01592370>

Study 190:

Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)

<http://ClinicalTrials.gov/show/NCT01463696>

Study 191:

A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

<http://ClinicalTrials.gov/show/NCT01283516>

Study 192:

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

<http://ClinicalTrials.gov/show/NCT01140607>

Study 193:

Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM)

<http://ClinicalTrials.gov/show/NCT01931098>

Study 194:

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01733004>

Study 195:

Phase 1 Safety Testing of SAR405838

<http://ClinicalTrials.gov/show/NCT01636479>

Study 196:

Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions

<http://ClinicalTrials.gov/show/NCT01847209>

Study 197:

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01416428>

Study 198:

Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

<http://ClinicalTrials.gov/show/NCT01661283>

Study 199:

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

<http://ClinicalTrials.gov/show/NCT00999804>

Study 200:

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

<http://ClinicalTrials.gov/show/NCT01802879>

Study 201:

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

<http://ClinicalTrials.gov/show/NCT01780545>

Study 202:

Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01362374>

Study 203:

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

<http://ClinicalTrials.gov/show/NCT01294670>

Study 204:

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

<http://ClinicalTrials.gov/show/NCT01642186>

Study 205:

Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01718899>

Study 206:

Phase I Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

<http://ClinicalTrials.gov/show/NCT01915498>

Study 207:

Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

<http://ClinicalTrials.gov/show/NCT01051063>

Study 208:

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

<http://ClinicalTrials.gov/show/NCT01769768>

Study 209:

Phase 1/2 Dose-Escalation, Safety, PK & PD Study of BVD-523, an ERK 1/2 Inhibitor, in Patients With Advanced Malignancies

<http://ClinicalTrials.gov/show/NCT01781429>

Study 210:

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

<http://ClinicalTrials.gov/show/NCT01587703>

Study 211:

A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

<http://ClinicalTrials.gov/show/NCT00634231>

Study 212:

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

<http://ClinicalTrials.gov/show/NCT01562899>

Study 213:

A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01799889>

Study 214:

A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001 AM4)

<http://ClinicalTrials.gov/show/NCT01358331>

Study 215:

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT00556049>

Study 216:

STA-9090 in Patients With Advanced Hepatocellular Cancer

<http://ClinicalTrials.gov/show/NCT01665937>

Study 217:

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

<http://ClinicalTrials.gov/show/NCT01742286>

Study 218:

HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

<http://ClinicalTrials.gov/show/NCT01387932>

Study 219:

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

<http://ClinicalTrials.gov/show/NCT01120457>

Study 220:

A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01262651>

Study 221:

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

<http://ClinicalTrials.gov/show/NCT01593228>

Study 222:

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

<http://ClinicalTrials.gov/show/NCT01321346>

Study 223:

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

<http://ClinicalTrials.gov/show/NCT01468688>

Study 224:

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

<http://ClinicalTrials.gov/show/NCT01763164>

Study 225:

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

<http://ClinicalTrials.gov/show/NCT01332266>

Study 226:

Concentration and Activity of Lapatinib in Vestibular Schwannomas

<http://ClinicalTrials.gov/show/NCT00863122>

Study 227:

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

<http://ClinicalTrials.gov/show/NCT01523587>

Study 228:

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

<http://ClinicalTrials.gov/show/NCT01693068>

Study 229:

A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants

<http://ClinicalTrials.gov/show/NCT01900652>

Study 230:

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

<http://ClinicalTrials.gov/show/NCT01483144>

Study 231:

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

<http://ClinicalTrials.gov/show/NCT01677910>

Study 232:

Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma

<http://ClinicalTrials.gov/show/NCT01909453>

Study 233:

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

<http://ClinicalTrials.gov/show/NCT01125800>

Study 234:

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

<http://ClinicalTrials.gov/show/NCT01801358>

Study 235:

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01602315>

Study 236:

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

<http://ClinicalTrials.gov/show/NCT01353222>

Study 237:

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

<http://ClinicalTrials.gov/show/NCT01430416>

Study 238:

Safety Study of PLX108-01 in Patients With Solid Tumors

<http://ClinicalTrials.gov/show/NCT01004861>

Study 239:

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01522872>

Study 240:

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01695590>

Study 241:

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01478048>

Study 242:

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

<http://ClinicalTrials.gov/show/NCT00916409>

Study 243:

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

<http://ClinicalTrials.gov/show/NCT01498328>

Study 244:

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

<http://ClinicalTrials.gov/show/NCT01480479>

Study 245:

A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01564537>

Study 246:

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01497093>

Study 247:

Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

<http://ClinicalTrials.gov/show/NCT01660633>

Study 248:

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

<http://ClinicalTrials.gov/show/NCT01582672>

Study 249:

Safety and Efficacy of Melphafen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

<http://ClinicalTrials.gov/show/NCT01897714>

Study 250:

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01615029>

Study 251:

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01323751>

Study 252:

Daratumumab (HuMax[®]-CD38) Safety Study in Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00574288>

Study 253:

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

<http://ClinicalTrials.gov/show/NCT01441973>

Study 254:

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01335399>

Study 255:

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01271504>

Study 256:

Tissue Procurement Substudy for Participants in Study CP-MGA271-01

<http://ClinicalTrials.gov/show/NCT01918930>

Study 257:

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

<http://ClinicalTrials.gov/show/NCT01784068>

Study 258:

A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

<http://ClinicalTrials.gov/show/NCT01602224>

Study 259:

Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00461045>

Study 260:

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01359657>

Study 261:

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01478581>

Study 262:

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01583283>

Study 263:

A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01762033>

Study 264:

A Study of Cabozantinib (XL184) vs. Everolimus in Subjects With Metastatic Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01865747>

Study 265:

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01746979>

Study 266:

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

<http://ClinicalTrials.gov/show/NCT01650805>

Study 267:

Combination Plerixafor (AMD3100) and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00903968>

Study 268:

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

<http://ClinicalTrials.gov/show/NCT01492673>

Study 269:

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

<http://ClinicalTrials.gov/show/NCT01208662>

Study 270:

A Phase I Study Of Panobinostat/Lenalidomide/ Bortezomib/Dex for Relapsed And Relapsed/ Refractory Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01965353>

Study 271:

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

<http://ClinicalTrials.gov/show/NCT01696461>

Study 272:

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01328626>

Study 273:

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

<http://ClinicalTrials.gov/show/NCT01807286>

Study 274:

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01380106>

Study 275:

A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma

<http://ClinicalTrials.gov/show/NCT01660750>

Study 276:

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

<http://ClinicalTrials.gov/show/NCT01351935>

Study 277:

Amgen 386 for Recurrent Glioblastoma

<http://ClinicalTrials.gov/show/NCT01290263>

Study 278:

Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

<http://ClinicalTrials.gov/show/NCT01339052>

Study 279:

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01668784>

Study 280:

A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01806064>

Study 281:

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

<http://ClinicalTrials.gov/show/NCT01547546>

Study 282:

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma

<http://ClinicalTrials.gov/show/NCT01844505>

Study 283:

Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs. Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

<http://ClinicalTrials.gov/show/NCT01927419>

Study 284:

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMab Clinical Trial Evaluation 064)

<http://ClinicalTrials.gov/show/NCT01783938>

Study 285:

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

<http://ClinicalTrials.gov/show/NCT01721746>

Study 286:

A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection

<http://ClinicalTrials.gov/show/NCT01682083>

Study 287:

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

<http://ClinicalTrials.gov/show/NCT01621490>

Study 288:

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01774344>

Study 289:

A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

<http://ClinicalTrials.gov/show/NCT01656642>

Study 290:

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

<http://ClinicalTrials.gov/show/NCT01673854>

Study 291:

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

<http://ClinicalTrials.gov/show/NCT01592045>

Study 292:

A Safety Study of SGN-CD19A for Leukemia and Lymphoma

<http://ClinicalTrials.gov/show/NCT01786096>

Study 293:

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

<http://ClinicalTrials.gov/show/NCT01790503>

Study 294:

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

<http://ClinicalTrials.gov/show/NCT01260506>

Study 295:

A Phase III Study of Oral LDE225 Versus (vs) Temozolomide (TMZ) in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

<http://ClinicalTrials.gov/show/NCT01708174>

Study 296:

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

<http://ClinicalTrials.gov/show/NCT01397825>

Study 297:

Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01727336>

Study 298:

A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

<http://ClinicalTrials.gov/show/NCT01473901>

Study 299:

A Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Subjects With Glioblastoma Multiforme in Combination With Radiation Plus Temozolomide or Temozolomide Alone

<http://ClinicalTrials.gov/show/NCT01800695>

Study 300:

Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma

<http://ClinicalTrials.gov/show/NCT01964235>

Study 301:

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

<http://ClinicalTrials.gov/show/NCT01519323>

Study 302:

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma

<http://ClinicalTrials.gov/show/NCT01696045>

Study 303:

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

<http://ClinicalTrials.gov/show/NCT01320085>

Study 304:

A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas

<http://ClinicalTrials.gov/show/NCT01815840>

Study 305:

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

<http://ClinicalTrials.gov/show/NCT01343277>

Study 306:

A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

<http://ClinicalTrials.gov/show/NCT00210665>

Study 307:

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

<http://ClinicalTrials.gov/show/NCT01440088>

Study 308:

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

<http://ClinicalTrials.gov/show/NCT01112527>

Study 309:

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

<http://ClinicalTrials.gov/show/NCT01339039>

Study 310:

A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas

<http://ClinicalTrials.gov/show/NCT00766467>

Study 311:

Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma

<http://ClinicalTrials.gov/show/NCT00821080>

Study 312:

Bosutinib in Adult Patients With Recurrent Glioblastoma

<http://ClinicalTrials.gov/show/NCT01331291>

Study 313:

STA-9090 (Ganetespib) in Metastatic Ocular Melanoma

<http://ClinicalTrials.gov/show/NCT01200238>

Study 314:

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

<http://ClinicalTrials.gov/show/NCT00577382>

Study 315:

Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

<http://ClinicalTrials.gov/show/NCT01495988>

Study 316:

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01363297>

Study 317:

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

<http://ClinicalTrials.gov/show/NCT00765921>

Study 318:

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

<http://ClinicalTrials.gov/show/NCT01125293>

Study 319:

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

<http://ClinicalTrials.gov/show/NCT01805037>

Study 320:

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

<http://ClinicalTrials.gov/show/NCT01546038>

Study 321:

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

<http://ClinicalTrials.gov/show/NCT01295710>

Study 322:

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01712490>

Study 323:

A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01578499>

Study 324:

Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas

<http://ClinicalTrials.gov/show/NCT01767792>

Study 325:

Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

<http://ClinicalTrials.gov/show/NCT01759303>

Study 326:

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

<http://ClinicalTrials.gov/show/NCT00752206>

Study 327:

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

<http://ClinicalTrials.gov/show/NCT01564784>

Study 328:

Bortezomib Plus Rituximab for EBV+ PTLD

<http://ClinicalTrials.gov/show/NCT01058239>

Study 329:

A Phase 2 Trial of East Indian Sandalwood Oil in the Treatment of Common Warts (Verruca Vulgaris)

<http://ClinicalTrials.gov/show/NCT01286441>

Study 330:

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

<http://ClinicalTrials.gov/show/NCT01693614>

Study 331:

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

<http://ClinicalTrials.gov/show/NCT01460160>

Study 332:

Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5

<http://ClinicalTrials.gov/show/NCT01744665>

Study 333:

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

<http://ClinicalTrials.gov/show/NCT01297543>

Study 334:

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT01349049>

Study 335:

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01874054>

Study 336:

A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

<http://ClinicalTrials.gov/show/NCT00866281>

Study 337:

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

<http://ClinicalTrials.gov/show/NCT01724346>

Study 338:

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01855750>

Study 339:

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

<http://ClinicalTrials.gov/show/NCT01777152>

Study 340:

A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

<http://ClinicalTrials.gov/show/NCT01722487>

Study 341:

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

<http://ClinicalTrials.gov/show/NCT01611090>

Study 342:

Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia

<http://ClinicalTrials.gov/show/NCT01826214>

Study 343:

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

<http://ClinicalTrials.gov/show/NCT01534715>

Study 344:

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

<http://ClinicalTrials.gov/show/NCT01363817>

Study 345:

A Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01659021>

Study 346:

Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

<http://ClinicalTrials.gov/show/NCT01489722>

Study 347:

CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

<http://ClinicalTrials.gov/show/NCT00659425>

Study 348:

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission

<http://ClinicalTrials.gov/show/NCT01757535>

Study 349:

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

<http://ClinicalTrials.gov/show/NCT00777036>

Study 350:

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

<http://ClinicalTrials.gov/show/NCT00790036>

Study 351:

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

<http://ClinicalTrials.gov/show/NCT00774345>

Study 352:

Phase II Phosphatidylinositol 3-Kinase (PI3K) Inhibitor in Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (NHL)

<http://ClinicalTrials.gov/show/NCT01660451>

Study 353:

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

<http://ClinicalTrials.gov/show/NCT01699152>

Study 354:

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01482962>

Study 355:

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

<http://ClinicalTrials.gov/show/NCT01883362>

Study 356:

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01421667>

Study 357:

Ofatumumab Maintenance Treatment vs. No Further Treatment in Relapsed CLL Responding to Induction Therapy

<http://ClinicalTrials.gov/show/NCT01039376>

Study 358:

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

<http://ClinicalTrials.gov/show/NCT01466179>

Study 359:

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

<http://ClinicalTrials.gov/show/NCT01736683>

Study 360:

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

<http://ClinicalTrials.gov/show/NCT01696084>

Study 361:

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

<http://ClinicalTrials.gov/show/NCT01476787>

Study 362:

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

<http://ClinicalTrials.gov/show/NCT01569295>

Study 363:

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNF α) Agents

<http://ClinicalTrials.gov/show/NCT01350804>

Study 364:

Treatment of Older Adults With Acute Lymphoblastic Leukemia

<http://ClinicalTrials.gov/show/NCT00973752>

Study 365:

Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)

<http://ClinicalTrials.gov/show/NCT00916630>

Study 366:

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01534078>

Study 367:

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)

<http://ClinicalTrials.gov/show/NCT01173679>

Study 368:

A Pilot Study of Oncaspar[®] + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01878708>

Study 369:

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

<http://ClinicalTrials.gov/show/NCT01961765>

Study 370:

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

<http://ClinicalTrials.gov/show/NCT00981799>

Study 371:

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

<http://ClinicalTrials.gov/show/NCT01096602>

Study 372:

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01476410>

Study 373:

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

<http://ClinicalTrials.gov/show/NCT00703820>

Study 374:

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

<http://ClinicalTrials.gov/show/NCT01397734>

Study 375:

Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

<http://ClinicalTrials.gov/show/NCT01772953>

Study 376:

Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

<http://ClinicalTrials.gov/show/NCT01199575>

Study 377:

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

<http://ClinicalTrials.gov/show/NCT01523977>

Study 378:

Everolimus in Treating Cutaneous T-cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01637090>

Study 379:

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

<http://ClinicalTrials.gov/show/NCT01713946>

Study 380:

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

<http://ClinicalTrials.gov/show/NCT01566695>

Study 381:

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

<http://ClinicalTrials.gov/show/NCT01289912>

Study 382:

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

<http://ClinicalTrials.gov/show/NCT01423851>

Diabetes

(23 clinical trials recruiting)

Study 1:

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes matching with Saxagliptin

<http://ClinicalTrials.gov/show/NCT01619059>

Study 2:

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

<http://ClinicalTrials.gov/show/NCT01609582>

Study 3:

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01541215>

Study 4:

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01720446>

Study 5:

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01719003>

Study 6:

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01734785>

Study 7:

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

<http://ClinicalTrials.gov/show/NCT01730534>

Study 8:

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01829464>

Study 9:

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01455857>

Study 10:

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01455870>

Study 11:

Evaluate Safety of T/I on Diabetic Subjects With Mild Obstructive Pulmonary Disease

<http://ClinicalTrials.gov/show/NCT00642616>

Study 12:

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

<http://ClinicalTrials.gov/show/NCT01712061>

Study 13:

Overnight Closed Loop Study in U.S.

<http://ClinicalTrials.gov/show/NCT01857973>

Study 14:

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01794143>

Study 15:

Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes

<http://ClinicalTrials.gov/show/NCT01681290>

Study 16:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 17:

Study Of Diabetic Nephropathy With Atrasentan

<http://ClinicalTrials.gov/show/NCT01858532>

Study 18:

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

<http://ClinicalTrials.gov/show/NCT01849965>

Study 19:

A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

<http://ClinicalTrials.gov/show/NCT01824407>

Study 20:

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

<http://ClinicalTrials.gov/show/NCT01455415>

Study 21:

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

<http://ClinicalTrials.gov/show/NCT01928381>

Study 22:

A Study to Evaluate the Efficacy and Safety of a Single Application of QUTENZA Compared to That of Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

<http://ClinicalTrials.gov/show/NCT01533428>

Study 23:

Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters

<http://ClinicalTrials.gov/show/NCT01819922>

Heart Disease

(36 clinical trials recruiting)

Study 1:

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

<http://ClinicalTrials.gov/show/NCT01475825>

Study 2:

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

<http://ClinicalTrials.gov/show/NCT01508910>

Study 3:

Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter

<http://ClinicalTrials.gov/show/NCT01253200>

Study 4:

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

<http://ClinicalTrials.gov/show/NCT01531374>

Study 5:

A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

<http://ClinicalTrials.gov/show/NCT01643330>

Study 6:

The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)

<http://ClinicalTrials.gov/show/NCT01665053>

Study 7:

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

<http://ClinicalTrials.gov/show/NCT01730534>

Study 8:

Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Patients

<http://ClinicalTrials.gov/show/NCT01626079>

Study 9:

BIOHELIX-I Bare Metal Stent Study

<http://ClinicalTrials.gov/show/NCT01612767>

Study 10:

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

<http://ClinicalTrials.gov/show/NCT01920711>

Study 11:

INcrease Of VAgal TonE in CHF

<http://ClinicalTrials.gov/show/NCT01303718>

Study 12:

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

<http://ClinicalTrials.gov/show/NCT01732822>

Study 13:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

<http://ClinicalTrials.gov/show/NCT01327846>

Study 14:

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

<http://ClinicalTrials.gov/show/NCT01314313>

Study 15:

MAESTRO-OL: Macitentan in Eisenmenger Syndrome To Restore Exercise Capacity (Open-Label)

<http://ClinicalTrials.gov/show/NCT01739400>

Study 16:

MAESTRO (Macitentan in Eisenmenger Syndrome To Restore Exercise Capacity)

<http://ClinicalTrials.gov/show/NCT01743001>

Study 17:

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

<http://ClinicalTrials.gov/show/NCT01639495>

Study 18:

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) Including GSPECT (Gated Single Photon Emission Computed Tomography)

<http://ClinicalTrials.gov/show/NCT01890434>

Study 19:

ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients

<http://ClinicalTrials.gov/show/NCT01424722>

Study 20:

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

<http://ClinicalTrials.gov/show/NCT01618669>

Study 21:

Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation

<http://ClinicalTrials.gov/show/NCT00855712>

Study 22:

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes)

<http://ClinicalTrials.gov/show/NCT01663402>

Study 23:

Post-Myocardial Infarction Remodeling Prevention Therapy

<http://ClinicalTrials.gov/show/NCT01213251>

Study 24:

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

<http://ClinicalTrials.gov/show/NCT01670981>

Study 25:

Right to Left Cardiac Shunt Detection

<http://ClinicalTrials.gov/show/NCT01773252>

Study 26:

AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

<http://ClinicalTrials.gov/show/NCT01495364>

Study 27:

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

<http://ClinicalTrials.gov/show/NCT01729871>

Study 28:

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

<http://ClinicalTrials.gov/show/NCT01556568>

Study 29:

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

<http://ClinicalTrials.gov/show/NCT01483183>

Study 30:

nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

<http://ClinicalTrials.gov/show/NCT01824394>

Study 31:

Vest Prevention of Early Sudden Death Trial and VEST Registry

<http://ClinicalTrials.gov/show/NCT01446965>

Study 32:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 33:

Early Elimination of Premature Ventricular Contractions in Heart Failure

<http://ClinicalTrials.gov/show/NCT01757067>

Study 34:

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

<http://ClinicalTrials.gov/show/NCT01777165>

Study 35:

A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

<http://ClinicalTrials.gov/show/NCT01602328>

Study 36:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

<http://ClinicalTrials.gov/show/NCT01101035>

Mental Illness

(39 clinical trials recruiting)

Study 1:

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

<http://ClinicalTrials.gov/show/NCT01727726>

Study 2:

A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders

<http://ClinicalTrials.gov/show/NCT01793441>

Study 3:

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

<http://ClinicalTrials.gov/show/NCT00550238>

Study 4:

L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults

<http://ClinicalTrials.gov/show/NCT01853280>

Study 5:

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

<http://ClinicalTrials.gov/show/NCT01741194>

Study 6:

An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

<http://ClinicalTrials.gov/show/NCT01715805>

Study 7:

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

<http://ClinicalTrials.gov/show/NCT01900665>

Study 8:

A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01767311>

Study 9:

Open Label Extension in Adults With Binge Eating Disorder (BED)

<http://ClinicalTrials.gov/show/NCT01657019>

Study 10:

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

<http://ClinicalTrials.gov/show/NCT01521663>

Study 11:

Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects

<http://ClinicalTrials.gov/show/NCT01887366>

Study 12:

ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

<http://ClinicalTrials.gov/show/NCT01457677>

Study 13:

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

<http://ClinicalTrials.gov/show/NCT01626378>

Study 14:

Efficacy and Safety of the PET Imaging Agent [18F] NAV4694 in Subjects With Probable Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01680588>

Study 15:

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01878292>

Study 16:

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01735630>

Study 17:

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

<http://ClinicalTrials.gov/show/NCT01467700>

Study 18:

A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01224106>

Study 19:

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients

<http://ClinicalTrials.gov/show/NCT01467713>

Study 20:

Beta-Amyloid Imaging With [18F] NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)

<http://ClinicalTrials.gov/show/NCT01812213>

Study 21:

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

<http://ClinicalTrials.gov/show/NCT01429116>

Study 22:

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01689233>

Study 23:

Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems

<http://ClinicalTrials.gov/show/NCT01743235>

Study 24:

Induction, STabilization, Adherence and Retention Trial (ISTART) of OX219 Buprenorphine/Naloxone

<http://ClinicalTrials.gov/show/NCT01908842>

Study 25:

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01689246>

Study 26:

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01436149>

Study 27:

Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa

<http://ClinicalTrials.gov/show/NCT01642550>

Study 28:

Study to Assess OX219 (Buprenorphine/Naloxone) for the Induction of Treatment of Opioid Dependence

<http://ClinicalTrials.gov/show/NCT01848054>

Study 29:

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

<http://ClinicalTrials.gov/show/NCT01361555>

Study 30:

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder

<http://ClinicalTrials.gov/show/NCT01674361>

Study 31:

Effects of Eltopazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults

<http://ClinicalTrials.gov/show/NCT01266174>

Study 32:

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01492374>

Study 33:

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

<http://ClinicalTrials.gov/show/NCT01518374>

Study 34:

Study Evaluating The Safety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

<http://ClinicalTrials.gov/show/NCT01712074>

Study 35:

Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder

<http://ClinicalTrials.gov/show/NCT01677182>

Study 36:

ABT-436 for Alcohol Dependence

<http://ClinicalTrials.gov/show/NCT01613014>

Study 37:

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

<http://ClinicalTrials.gov/show/NCT01480232>

Study 38:

Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients

<http://ClinicalTrials.gov/show/NCT01504958>

Study 39:

The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa

<http://ClinicalTrials.gov/show/NCT00759772>

Stroke

(12 clinical trials recruiting)

Study 1:

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

<http://ClinicalTrials.gov/show/NCT00856661>

Study 2:

Glyburide Advantage in Malignant Edema and Stroke—Remedy Pharmaceuticals

<http://ClinicalTrials.gov/show/NCT01794182>

Study 3:

Study to Examine the Effects of MultiStem in Ischemic Stroke

<http://ClinicalTrials.gov/show/NCT01436487>

Study 4:

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

<http://ClinicalTrials.gov/show/NCT01208233>

Study 5:

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

<http://ClinicalTrials.gov/show/NCT00826059>

Study 6:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 7:

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

<http://ClinicalTrials.gov/show/NCT01730534>

Study 8:

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

<http://ClinicalTrials.gov/show/NCT01732822>

Study 9:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

<http://ClinicalTrials.gov/show/NCT01327846>

Study 10:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

<http://ClinicalTrials.gov/show/NCT01101035>

Study 11:

Right to Left Cardiac Shunt Detection

<http://ClinicalTrials.gov/show/NCT01773252>

Study 12:

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

<http://ClinicalTrials.gov/show/NCT01259297>



Pharmaceutical Research and Manufacturers of America
950 F Street, NW, Washington, DC 20004

www.phrma.org